SLC5A2 and Hypoglycemia: Interestingly, during clinical development of SGLT2 inhibitors hardly any hypoglycaemia was observed due to the following reasons: first, glucose excretion decreases along with decreasing plasma glucose levels and; second, counter-regulatory mechanisms are not affected by SGLT2 inhibition as gliflozins act independently from insulin.